Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Mononuclear phagocytes are a widely distributed family of cells contributing to innate and adaptive immunity. Circulating monocytes and tissue macrophages participate in all stages of SARS COVID-19. They contribute to comorbidities predisposing to clinical infection, virus resistance and dissemination, and to host factors that determine disease severity, recovery and sequelae. Assays are available to detect viral infection and antibody responses, but no adequate tests have been developed to measure the activation level of monocytes and tissue macrophages, and the risk of progression to a fatal hyperinflammatory syndrome. Blood monocytes provide a window on the systemic immune response, from production to tissue recruitment, reflecting the impact of infection on the host. Ready availability of blood makes it possible to monitor severity and the risk of potentially lethal complications, by developing tests to assess the status of monocyte activation and its potential for further inflammatory dysregulation after recruitment to tissues and during recovery.

Original publication

DOI

10.1016/j.ebiom.2020.102964

Type

Journal article

Journal

Ebiomedicine

Publication Date

09/2020

Volume

59

Keywords

Activation, COVID-19, Csf1r, Csf2r, Csf3r, Macrophages, Monocyte, Betacoronavirus, COVID-19, Comorbidity, Coronavirus Infections, Cytokines, Humans, Immunity, Innate, Macrophages, Monocytes, Pandemics, Pneumonia, Viral, SARS-CoV-2, Severity of Illness Index